Indicators of survival duration in ovarian cancer and implications for aggressiveness of care

Cancer

Volumn 112, Issue 10, 2008, Pages 2221-2227

  Von Gruenigen, Vivian ^a,b   Daly, Barbara ^c   Gibbons, Heidi ^a,b   Hutchins, Jessica ^a,b   Green, Andrew ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Aggressiveness of care; Chemotherapy; End of life; Ovarian cancer; Survival

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CHI SQUARE TEST; CONTROLLED STUDY; DEPENDENT VARIABLE; DISEASE DURATION; EMERGENCY WARD; FEMALE; HOSPITALIZATION; HUMAN; INTESTINE OBSTRUCTION; LIFESPAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE REGRESSION; OVARY CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; STUDENT T TEST; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER CARE FACILITIES; CHEMOTHERAPY, ADJUVANT; EMERGENCY TREATMENT; FEMALE; HOSPITALIZATION; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PALLIATIVE CARE; PLEURAL EFFUSION, MALIGNANT; POSTOPERATIVE COMPLICATIONS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 43049138365     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23391     Document Type: Article

References (16)

1. Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. Chemotherapy use among medicare beneficiaries at the end of life. Ann Intern Med. 2003;138:639-643.
2. von Gruenigen VE, Frasure HE, Reidy AM, Gil KM. Clinical disease course during the last year in ovarian cancer. Gynecol Oncol. 2003;90:619-624.
3. LoCoco S, Covens A, Carney M, et al. Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study. Gynecol Oncol. 1995:59:194-199.
4. Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME. Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 2000;160:861-868.
5. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the "aggressiveness of cancer care" near the end of life. J Clin Oncol. 2004;22:315-321.
6. Specifications of national voluntary consensus standards for symptom management and end-of-life care in cancer patients. The National Quality Forum. Available at: http://www.qualityforum.org/projects/ongoing/cacner/index.asp Accessed January 15, 2007.
7. Hoskins PJ, Le N. Identifying patients unlikely to benefit from further chemotherapy, a descriptive study of outcome at each relapse in ovarian cancer. Gynecol Oncol. 2005;97:862-869.
8. Silber JH, Rosenbaum PR, Polsky D, et al. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy? J Clin Oncol. 2007;25:1169-1175.
9. Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol. 2006;24:3490-3496.
10. Brown D, Roberts JA, Elkins TE, Larson D, Hopkins M. Hard choices: the gynecologic cancer patient's end-of-life preferences. Gynecol Oncol. 1994:55(3 pt 1):355-362.
11. Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC. Treatment preferences in recurrent ovarian cancer. Gynecol Oncol. 2002;86:200-211.
12. Glare P, Virik K, Jones M, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ. 2003;327:195-200.
13. Gripp S, Moeller, Bolke E, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol. 2007;25:3313-3320.
14. Connor SR, Pyenson B, Fitch K, Spence C, Iwasaki K. Comparing hospice and nonhospice patient survival among patients who die within a 3-year window. J Pain Symptom Manage. 2007;33:238-246.
15. Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM. Patterns of functional decline at the end of life. JAMA. 2003;289:2387-2392.
16. Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 2006;102:425-428.